Study Name:
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Targeted Disease(s):
Pulmonary Fibrosis
Purpose of Study:
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
Study Dates:
September 14, 2023 - October 26, 2026
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Funding Source:
Bristol-Myers Squibb
Contact:
BMS Clinical Trials Contact Center
855-907-3286
Clinical.Trials@bms.com
ClinicalTrails.gov Identifier:
NCT06003426
